Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid
malignancies consists of two parts:
1. Single Dose Period - will characterise the absorption, metabolism, excretion and
pharmacokinetics of a single oral dose of [14C]AZD2014 from the body
2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour
activity of multiple doses of AZD2014 when given as a monotherapy or given in
combination with paclitaxel or fulvestrant.